University of Lorraine

About: University of Lorraine is a education organization based out in Nancy, France. It is known for research contribution in the topics: Population & Context (language use). The organization has 11942 authors who have published 25010 publications receiving 425227 citations. The organization is also known as: Lorraine University.

Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders.

Abstract: C-reactive protein (CRP) is a sensitive biomarker of chronic low-grade inflammation and is associated with multiple complex diseases. The genetic determinants of chronic inflammation remain largely unknown, and the causal role of CRP in several clinical outcomes is debated. We performed two genome-wide association studies (GWASs), on HapMap and 1000 Genomes imputed data, of circulating amounts of CRP by using data from 88 studies comprising 204,402 European individuals. Additionally, we performed in silico functional analyses and Mendelian randomization analyses with several clinical outcomes. The GWAS meta-analyses of CRP revealed 58 distinct genetic loci (p < 5 × 10−8). After adjustment for body mass index in the regression analysis, the associations at all except three loci remained. The lead variants at the distinct loci explained up to 7.0% of the variance in circulating amounts of CRP. We identified 66 gene sets that were organized in two substantially correlated clusters, one mainly composed of immune pathways and the other characterized by metabolic pathways in the liver. Mendelian randomization analyses revealed a causal protective effect of CRP on schizophrenia and a risk-increasing effect on bipolar disorder. Our findings provide further insights into the biology of inflammation and could lead to interventions for treating inflammation and its clinical consequences.

Adding Virtualization Capabilities to the Grid’5000 Testbed

Abstract: Almost ten years after its premises, the Grid’5000 testbed has become one of the most complete testbed for designing or evaluating large-scale distributed systems. Initially dedicated to the study of High Performance Computing, the infrastructure has evolved to address wider concerns related to Desktop Computing, the Internet of Services and more recently the Cloud Computing paradigm. This paper present recent improvements of the Grid’5000 software and services stack to support large-scale experiments using virtualization technologies as building blocks. Such contributions include the deployment of customized software environments, the reservation of dedicated network domain and the possibility to isolate them from the others, and the automation of experiments with a REST API. We illustrate the interest of these contributions by describing three different use-cases of large-scale experiments on the Grid’5000 testbed. The first one leverages virtual machines to conduct larger experiments spread over 4000 peers. The second one describes the deployment of 10000 KVM instances over 4 Grid’5000 sites. Finally, the last use case introduces a one-click deployment tool to easily deploy major IaaS solutions. The conclusion highlights some important challenges of Grid’5000 related to the use of OpenFlow and to the management of applications dealing with tremendous amount of data.

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

Abstract: Background Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and improve outcomes for patients with worsening chronic heart failure and underlying coronary artery disease. Methods In this double-blind, randomized trial, 5022 patients who had chronic heart failure, a left ventricular ejection fraction of 40% or less, coronary artery disease, and elevated plasma concentrations of natriuretic peptides and who did not have atrial fibrillation were randomly assigned to receive rivaroxaban at a dose of 2.5 mg twice daily or placebo in addition to standard care after treatment for an episode of worsening heart failure. The primary efficacy outcome was the composite of death from any cause, myocardial infarction, or stroke. The principal safety outcome was fatal bleeding or bleeding into a critical space with a potential for causing permanent di...